Spironolactone for hirsutism

Spironolactone (also known as Aldactone) is arguably the number one hirsutism treatment of choice for dermatologists in the US. Spironolactone has antiandrogenic effects that may enhance treatment of several androgen-excess conditions, particularly severe hirsutism. Some dermatologists suggest that the effects of spironolactone are somewhat inferior to cyproterone acetate (CPA). However, CPA is not available in the US.

Spironolactone has several properties that make it suitable for use in treating hirsutism. It interferes with the production of testosterone and it increases the metabolism of any testosterone that is produced. Spironolactone binds to cell androgen receptors and blocks them from binding to naturally produced androgens. In addition with long term spironolactone use, there is a gradual reduction in 5 alpha reductase activity. It is this enzyme that converts testosterone to the more potent, hair follicle stimulating, dihydrotestosterone.

Treatment protocols may involve continuous spironolactone use at 50mg to 200mg per day or cyclic use. For example 50mg or 100mg twice daily from the 4th to the 22nd day of the menstrual cycle. Numerous treatment protocols involving spironolactone have been used in different studies, but no particular treatment approach has been shown to be significantly superior. Combination therapy with an oral contraceptive pill or dexamethasone appears to have an improved beneficial effect on hirsutism and limits side effects.

Side effects with spironolactone are generally transient. As with all antiandrogens , spironolactone use should be avoided during pregnancy and in women who have a family history of breast cancer, although there is no proven association between spironolactone and breast malignancy.

{{kat note: Visit the source link above for a link to MORE aldactone resources – many of the below references are HOT links at the source page}}

Spironolactone for hirsutism references

Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf). 2000 May;52(5):587-94.
Erenus M, Yucelten D, Durmusoglu F, Gurbuz O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril. 1997 Dec;68(6):1000-3.
Erenus M, Yucelten D, Gurbuz O, Durmusoglu F, Pekin S. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil Steril. 1996 Aug;66(2):216-9.
Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab. 1995 Jan;80(1):233-8.
Crosby PD, Rittmaster RS. Predictors of clinical response in hirsute women treated with spironolactone. Fertil Steril. 1991 Jun;55(6):1076-81.
Prezelj J, Kocijancic A, Andolsek L. Dexamethasone and spironolactone in the treatment of non-tumorous hyperandrogenism. Gynecol Endocrinol. 1989 Dec;3(4):281-8.
Barth JH, Cherry CA, Wojnarowska F, Dawber RP. Spironolactone is an effective and well tolerated systemic antiandrogen therapy for Hirsute women. J Clin Endocrinol Metab. 1989 May;68(5):966-70.
Helfer EL, Miller JL, Rose LI. Side-effects of spironolactone therapy in the hirsute woman. J Clin Endocrinol Metab. 1988 Jan;66(1):208-11.
Lunde O, Djoseland O. A comparative study of Aldactone and Diane in the treatment of hirsutism. J Steroid Biochem. 1987 Aug;28(2):161-5.
Ylostalo P, Heikkinen J, Kauppila A, Pakarinen A, Jarvinen PA. Low-dose spironolactone in the treatment of female hirsutism. Int J Fertil. 1987 Jan-Feb;32(1):41-5.
Pittaway DE, Maxson WS, Wentz AC. Spironolactone in combination drug therapy for unresponsive hirsutism. Fertil Steril. 1985 Jun;43(6):878-82.
Cumming DC, Yang JC, Rebar RW, Yen SS. Treatment of hirsutism with spironolactone. JAMA. 1982 Mar 5;247(9):1295-8.
Marcondes JA, Minanni SL, Luthold WW, Lerario AC, Nery M, Mendonca BB, Wajchenberg BL, Kirschner MA. The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women. J Endocrinol Invest. 1995 Jun;18(6):431-5.
McMullen GR, Van Herle AJ. Hirsutism and the effectiveness of spironolactone in its management. J Endocrinol Invest. 1993 Dec;16(11):925-32.
Wild RA, Demers LM, Applebaum-Bowden D, Lenker R. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone. Contraception. 1991 Aug;44(2):113-24.
Cumming DC. Use of spironolactone in treatment of hirsutism. Cleve Clin J Med. 1990 May;57(3):285-7.
Hughes BR, Cunliffe WJ. Tolerance of spironolactone. Br J Dermatol. 1988 May;118(5):687-91.
Board JA, Rosenberg SM, Smeltzer JS. Spironolactone and estrogen-progestin therapy for hirsutism. South Med J. 1987 Apr;80(4):483-6.
Evans DJ, Burke CW. Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome. J R Soc Med. 1986 Aug;79(8):451-3.
Tremblay RR. Treatment of hirsutism with spironolactone. Clin Endocrinol Metab. 1986 May;15(2):363-71.
Chapman MG, Katz M, Dowsett M, Hague W, Jeffcoate SL, Dewhurst CJ. Spironolactone in the treatment of hirsutism. Acta Obstet Gynecol Scand. 1986;65(4):349-50.
Chapman MG, Dowsett M, Dewhurst CJ, Jeffcoate SL. Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism. Br J Obstet Gynaecol. 1985 Sep;92(9):983-5.
Thomas AK, Slobodniuk R, Taft J, Cooper M, Montalto J, Jerums G. The treatment of hirsutism: experience with cyproterone acetate and spironolactone. Australas J Dermatol. 1985 Apr;26(1):19-24.
Lobo RA, Shoupe D, Serafini P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril. 1985 Feb;43(2):200-5.
Messina M, Manieri C, Biffignandi P, Massucchetti C, Novi RF, Molinatti GM. Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. J Endocrinol Invest. 1983 Feb;6(1):23-7.
Ross HD. Tumorigenic aspect of spironolactone. West J Med. 1981 Sep;135(3):244.
Shapiro G, Evron S. A novel use of spironolactone: treatment of hirsutism. J Clin Endocrinol Metab. 1980 Sep;51(3):429-32.
Ober KP, Hennessy JF. Spironolactone therapy for hirsutism in a hyperandrogenic woman. Ann Intern Med. 1978 Nov;89(5 Pt 1):643-4.

Leave a Comment